Breaking News
January 16, 2018 - Cycling does not negatively impact sexual and urinary health finds study
January 16, 2018 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
January 16, 2018 - Just How Often Do Patients Turn Post-Surgical Opioids Into a Habit?
January 16, 2018 - Opioid addiction – Genetics Home Reference
January 16, 2018 - Incomplete revascularization in PCI linked to higher mortality
January 16, 2018 - Machine learning algorithm uses brain scans to predict language ability in deaf children
January 16, 2018 - Penn scientists identify new therapeutic target for treatment of melanoma
January 16, 2018 - The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health
January 16, 2018 - Early influenza testing is critical to prevent serious complications
January 16, 2018 - Study Gets to the Core of Back Pain in Runners
January 16, 2018 - Year in Review: Ophthalmology | Medpage Today
January 16, 2018 - ClinicalTrials.gov: Marijuana Use
January 16, 2018 - Researchers create novel compound targeting melanoma cells
January 16, 2018 - FDA grants approval for first drug to treat inherited breast cancer
January 16, 2018 - Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells
January 16, 2018 - Fresh, Frozen Embryos Equal in IVF
January 16, 2018 - Research shows biological clocks could improve brain cancer treatment
January 16, 2018 - Dire view from within accident and emergency wards of England and Wales
January 16, 2018 - Study reveals how devastating mitochondrial diseases strike families without any previous history
January 16, 2018 - Experts look for ways to standardize treatments for pediatric rheumatic diseases
January 16, 2018 - Teens who watch TV shows with ads likely to eat more junk food
January 16, 2018 - Aztec apocalypse found to be Salmonella outbreak
January 16, 2018 - Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Leber’s Hereditary Optic Neuropathy
January 16, 2018 - Three Ineffective Institutional Approaches to Quality Improvement in Healthcare
January 16, 2018 - New technology accelerates autism diagnosis and treatment
January 16, 2018 - Preterm babies likely to experience delays in auditory brain development, study reveals
January 16, 2018 - Research sheds new light on genetic, environmental factors that promote prostate cancer metastasis
January 16, 2018 - Mitochondrial impairment may actually protect the brain in Parkinson’s disease, study shows
January 15, 2018 - Energy drinks can have adverse health effects on youth, study reveals
January 15, 2018 - 60° Pharmaceuticals (60P) Submits New Drug Application to US FDA for Antimalarial Drug Tafenoquine
January 15, 2018 - Wanted: ‘Breathalyzer’ for Cannabis Use
January 15, 2018 - Surfers more likely to get antibiotic resistant E. coli in their guts
January 15, 2018 - “Baby brain” a real clinical entity finds study
January 15, 2018 - Whole of Britain to be put on a diet plan come March
January 15, 2018 - Neighborhood Deprivation Linked to Heart Failure
January 15, 2018 - Omega-3 and Omega-6 fatty acid intake may affect lupus outcomes
January 15, 2018 - Scientists discover new enzyme that could reduce obesity rates
January 15, 2018 - Evidence suggests two patterns of early symptoms precede and predict later BD risk
January 15, 2018 - Harm minimization approach for smoking cessation with e-cigarettes
January 15, 2018 - Surgery or Antibiotics for Appendicitis? Here’s What Patients Chose
January 15, 2018 - ASH: Frailty Screening Tool Guides Therapy in Elderly
January 15, 2018 - Study shows video games could cut dementia risk in seniors
January 15, 2018 - Common Food Additive Promoting C. diff?
January 15, 2018 - Mild traumatic brain injury causes long-term damage in mice
January 15, 2018 - Circadian clock proteins set the pace of plant growth
January 15, 2018 - Two proteins shown to regenerate brain in Parkinson’s disease
January 15, 2018 - Jotting down tasks may ease falling asleep, study says
January 15, 2018 - Chi-Med Initiates Fruquintinib U.S. Clinical Trials
January 15, 2018 - Cell-Free DNA May Help Pinpoint Breast Ca Survival
January 15, 2018 - What goes on inside a medically supervised injection facility?
January 15, 2018 - Research provides new model to better ascertain HIV mortality rates in Zambia
January 15, 2018 - Genetic analysis can enhance outcomes of depression treatment
January 15, 2018 - Variations in bacterial strains can trigger varying immune responses, study states
January 15, 2018 - TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
January 15, 2018 - HIV Vaccine Shows ‘Positive Signal’ in Small Study
January 15, 2018 - Researchers demonstrate RAS dimers are essential for cancer
January 15, 2018 - Groundbreaking report highlights plan to end bowel cancer
January 15, 2018 - Doc Aspires to Bring ‘Medicine the Musical’ to Off-Broadway
January 15, 2018 - Does an exploding brain network cause chronic pain?
January 15, 2018 - Researchers use novel PET tracer to assess myelin damage in mouse models of MS
January 15, 2018 - Survival strategy of mRNAs during sugar deficiency in the cell
January 15, 2018 - Hormone Therapy May Ease Depression Linked to Menopause
January 15, 2018 - Pain Sensitization Declines After Bariatric Tx in Obese Patients
January 15, 2018 - C7 nerve transfer improves function in spastic arm paralysis
January 15, 2018 - Australian kids are drinking and smoking far less than before
January 15, 2018 - Worsening of anxiety symptoms may be early indicator of Alzheimer’s disease
January 15, 2018 - Early testing for influenza symptoms can limit severe, life-threatening disease
January 15, 2018 - Exposure to estrogen-mimicking compounds may reverse effects of breast cancer treatment
January 15, 2018 - Lipids May Play Key Role in Abdominal Aneurysm
January 15, 2018 - Raw Dough’s a Raw Deal and Could Make You Sick
January 15, 2018 - Thinking about germs makes people concerned about how they look
January 15, 2018 - Pitt scientists develop new guidelines to alleviate EMS personnel fatigue
January 15, 2018 - Discovery suggests new approach for targeting most-wanted molecular culprits in cancer
January 14, 2018 - Rhizen Pharmaceuticals S.A. Receives FDA Orphan-Drug Designation for Tenalisib (RP6530) for Treatment of Peripheral T-Cell Lymphoma (PTCL)
January 14, 2018 - Adding Enzyme to Chemo Combo Improves Outcomes in Pancreatic CA
January 14, 2018 - Research suggests ways to help mentally ill in Ghana’s prayer camps
January 14, 2018 - U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer
January 14, 2018 - Availability of qualified nurses in hospitals affects patient satisfaction
January 14, 2018 - Prostate cancer’s gene-determined ‘immune landscape’ dictates tumor progression
January 14, 2018 - Online CME: Is This Your First Choice?
Tofacitinib a Winner in PsA

Tofacitinib a Winner in PsA

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • In tumor necrosis factor-inhibitor (TNFi)-naïve patients with active psoriatic arthritis (PsA), oral tofacitinib was superior to placebo in a phase III trial.
  • Note that the efficacy of tofacitinib in PsA appears similar to what is seen with biologics such as adalimumab which was used as a comparator control in the trial.

Every year at this time, MedPage Today‘s writers select a few of the most important stories published earlier in the year and examine what happened afterward. One of those original stories, which appeared June 19, is republished below; click here to read the follow-up.

MADRID — The JAK inhibitor tofacitinib (Xeljanz) shows promise as a new oral treatment for psoriatic arthritis (PsA), a phase III trial suggested.

Among 422 patients with active PsA who had previously had an inadequate response to conventional disease-modifying anti-rheumatic drug treatment, 20% responses according to the criteria of the American College of Rheumatology (ACR20) were seen at 3 months in 33% of patients randomized to placebo, in 50% of patients receiving tofacitinib, 5 mg twice daily (P<0.05 versus placebo), in 61% of those given tofacitinib, 10 mg twice daily (P<0.0001), and in 52% of those receiving subcutaneous adalimumab (Humira), 40 mg every 2 weeks (P<0.05), according to Philip J. Mease, MD, of the University of Washington in Seattle.

“The efficacy of tofacitinib in PsA appears similar to what is seen with biologics such as adalimumab,” he said in a press briefing at the at the annual European Congress of Rheumatology, organized by the European League Against Rheumatism.

“Many patients would like the option of having an oral option for treatment,” he said.

The study was a 12-month trial that included patients who fulfilled the CASPAR criteria for PsA, had at least 3 tender and swollen joints, had active plaque psoriasis, and were tumor necrosis factor-naive. The first 3 months were placebo-controlled, and thereafter patients receiving placebo were re-randomized to 5 or 10 mg tofacitinib twice daily.

The study was not designed for superiority or non-inferiority; adalimumab was a comparator control. The analysis was done according to the nonresponder imputation method, which is the most strict way of looking at the data, Mease explained.

A total of 88% of patients completed the study, with most dropouts — as expected — being from the placebo arm.

Almost all patients were white, slightly more than half were women, and mean age was 48. Disease duration ranged from 5 to 7 years.

Already by week 2, ACR20 response rates were 22.4% and 31.7%, respectively, for the 5- and 10-mg groups compared with 5.7% in the placebo group (P<0.001 and P<0.0001, respectively).

On the Health Assessment Questionnaire Disability Index, changes at 3 months were -0.18 for the placebo group, -0.35 for the 5-mg tofacitinib group (P<0.05), -0.40 in the tofacitinib group (P<0.001), and -0.38 in the adalimumab group (P<0.05).

For enthesitis, a statistically significant change of -1.5 was seen at 3 months in the 10-mg group compared with -0.4 in the placebo group, while for dactylitis the changes were -5.5 versus -2 in those two groups.

The Psoriasis Area and Severity Index 75% (PASI 75) improvement at 3 months was seen in 43% of patients in the 5-mg group and 44% of those in the 10-mg group, which was similar to what was seen in the adalimumab group. By 12 months, the PASI 75 response was achieved by 56% of the 5-mg group and by 67% of the 10-mg group.

“This is the first time we’ve seen prolonged data out to the 1-year mark with the 5 mg twice daily dose. This was not studied in the psoriasis program for tofacitinib,” Mease noted.

In addition, the vast majority (91%) of patients were considered radiographic non-progressors at 12 months, meaning that an increase in total Sharp score was 0.5 or less.

The most common adverse events were upper respiratory tract infections, seen in 7.5% to 10.6%, nasopharyngitis, in 7.5% to 11.5%, and headache, in 3.8% to 10.6%.

Serious adverse events were reported in eight patients in the 5-mg arm, in four patients in the 10-mg arm, and in nine patients in the adalimumab arm. A single death occurred, in a patient originally in the placebo group who was re-randomized to the 5-mg tofacitinib group. This was not attributed to the study medication.

Overall there were four malignancies among patients receiving tofacitinib. One of these was a urothelial bladder cancer noted at day 1, and a second was a squamous cell carcinoma found at day 11, “which likely were cancers that were missed as patients were enrolled,” he said.

The study was funded by Pfizer.

Mease disclosed relevant relationships with Pfizer, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Sun, UCB, Celgene, Crescendo, CORRONA, Dermira, Merck, Zynerba, and Genentech.

2017-12-28T13:00:00-0500

Tagged with:

About author

Related Articles